The PRECIOUS Study: Predicting Crohn's & Colitis Outcomes in the United States

Brief description of study

The purpose of this study is to evaluate a test called PredictSURE IBD™ in the US population. PredictSURE IBD™ is a “prognostic” blood test administered to people who have a confirmed diagnosis of Crohn’s disease or ulcerative colitis (collectively inflammatory bowel disease, IBD). The test is considered “prognostic”, which means that it predicts how the disease will behave in the long-term in the patient receiving the test. The test will help inform both the patient and his or her clinician about the likelihood of experiencing frequent disease relapses and the need for escalations in the medication prescribed to control the disease symptoms. The ability of the test to predict disease course has already been tested in a UK-based population. This study aims to examine the performance of the test in a US population, and in the US healthcare system.

Clinical Study Identifier: s19-00739
Principal Investigator: Lea Ann Chen.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.